Therefore, this study aimed to examine the effects of WEE1 expression, p53 mutations, and KRAS mutations on the clinicopathological features and prognosis of CRC and the effects of WEE1 inhibitors in various CRC cell lines with different mutational statuses. This evidence concerns the gene KRAS and colorectal carcinoma.